NEW YORK: American drugmaker Pfizer is close to a deal to purchase Global Blood Therapeutics, which manufactures a recently approved drug against sickle-cell anemia, for $5 billion, the Wall Street Journal has reported.
Pfizer, one of the top makers of Covid-19 vaccines, hopes to conclude talks with GBT within days, the newspaper said Friday, citing people close to the negotiations.
But it said other takeover candidates remain in the running.
GBT's sickle-cell treatment, marketed as Oxbryta, was authorized for those over 12 years old in 2019 but gained federal approval in December for children aged four to 11. The blood disorder affects millions.
Sales of Oxbryta helped the laboratory generate first-quarter turnover of $55 million (up 41 per cent), while the company registered a net loss of $81.4 million.
GBT, which is based in San Francisco, California, is to publish its second-quarter numbers on Monday.
Pfizer, for its part, saw its second-quarter turnover jump by 47 percent — to a record $27.74 billion — boosted by sales of its Covid vaccine and pills.
Its net profit soared by 78 percent, to $9.9 billion.
GBT shares on the New York Stock Exchange were up 33.03 per cent at the close on Friday, at $63.84, for a market capitalization of more than $4 billion.
Pfizer shares slipped by 1.18 per cent, to $49.27.
Study answers whether "one size fits all” idea when it comes to water consumption is a fact or just a myth
The EU wants to slash premature deaths related to fine particulate matter pollution by 55% in 2030 compared to 2005...
Mother-to-be Michelle Johnson underwent fetal surgery to allow surgeons to fight against a rare condition in her child
China's daily COVID cases have hit a record high since the beginning of the pandemic, official data showed Thursday,...
Scientists at UCL wanted to study the progression of Usher syndrome which causes the slow development of blindness
Pathogens were associated with 7.7 million deaths — 13.6% of global total — in 2019, year before COVID-19 pandemic...